COGNITION THERAPEUTICS INC·4

May 4, 4:01 PM ET

Doyle John Brendan 4

Research Summary

AI-generated summary

Updated

Cognition Therapeutics (CGTX) CFO John Doyle Withholds 8,567 Shares for Taxes

What Happened

  • John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics (CGTX), had 8,567 shares withheld on May 1, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).
  • The shares were valued at $1.28 each, for a total of $10,966 (reported as a disposition). This was a withholding transaction, not an open-market sale or purchase.

Key Details

  • Transaction date: 2026-05-01; Filing date: 2026-05-04 (filed timely).
  • Price per share: $1.28; Shares withheld/disposed: 8,567; Total value reported: $10,966.
  • Shares owned after the transaction: not specified in the filing.
  • Footnote: F1 — shares were withheld by the issuer to cover tax withholding obligations on vested RSUs (routine tax withholding).
  • Transaction code: F (tax withholding), not a purchase (P) or sale (S) for cash.

Context

  • This was a routine tax-withholding action tied to RSU vesting (a common way companies satisfy an insider’s tax bill by withholding shares). It reduces the number of net shares the insider receives but does not necessarily indicate a change in the insider’s view of the company.
  • Retail investors typically view withholding transactions as administrative; purchases are generally more informative about insider sentiment.